发明名称 Compositions and methods of using lamellar bodies for modifying linear biological macromolecules
摘要 Compositions comprising therapeutically effective amounts of lamellar bodies for the modification of linear macromolecules are disclosed. These lamellar compositions are useful in the treatment of conditions or diseases characterized by a preponderance of heavy mucous secretions, such as otitis media, cystic fibrosis, bronchitis, sinusitis and nasal congestion. Methods of treating these diseases and conditions by administering a therapeutically effective amount of a composition to a patient requiring such treatment are also disclosed.
申请公布号 US9173901(B2) 申请公布日期 2015.11.03
申请号 US200812313724 申请日期 2008.11.24
申请人 LAMELLAR THERAPEUTICS LIMITED 发明人 Dobbie James
分类号 A61K9/127;A61K35/12;A61K9/00;A61K31/575;A61K31/683;A61K31/685;A61K31/688 主分类号 A61K9/127
代理机构 Klauber & Jaskson LLC 代理人 Klauber & Jaskson LLC
主权项 1. A method for increasing the fluidity of a subject's surface airway surface fluid and restoring mucociliary clearance of secretions of the respiratory tract comprising applying an aerosol composition comprising lamellar bodies, wherein said lamellar bodies comprise phosphatidylcholine, sphingomyelin, phosphatidyl ethanolamine, phosphatidyl serine, phosphatidyl inositol and cholesterol, wherein said lamellar bodies are phospholipid multilamellar bilayered structures which comprise about 44-70% phosphatidylcholine, about 15-23% sphingomyelin, about 6-10% phosphatidyl ethanolamine, about 2-6% phosphatidyl serine, about 2-4% phosphatidyl inositol and about 4-12% cholesterol by weight to a subject's respiratory passages to modify the physical properties of linear macromolecules of the type mucous DNA, actin and alginate in pathologically altered secretions, wherein the pathologically altered secretions are present in a condition selected from the group consisting of cystic fibrosis, bronchiectasis, chronic obstructive pulmonary disease and nasal congestion.
地址 Glasgow GB